 |
|
|
|
August 2001 Cover
|
|
A preliminary study by Bristol Myers Squibb suggests that a new AIDS drug may avoid the heart problems linked to many medications that are currently available. The study, presented last
month at the International AIDS Society meeting in Buenos Aires, compared atazanavir, an experimental protease inhibitor, to an older drug in 467 HIV patients. Cholesterol and triglyceride
counts increased only slightly or dropped among patients on the new drug, compared with increases higher than 16 percent for those on the older drug. Physicians have become increasingly
concerned about increases in cholesterol and other blood markers linked to heart disease among people on protease inhibitors.
Editor's Note: from USA Today
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
